Bristol-Myers Squibb

Healthcare

2seventy Bio (NASDAQ: TSVT) Discontinues Enrollment in Key Blood Cancer Therapy Trial

Maria Reed / 25 September 2024

2seventy Bio (NASDAQ: TSVT) will discontinue enrolling patients in a late-stage study of its cell therapy Abecma, developed in partnership […]

2seventy Bio (NASDAQ: TSVT) Discontinues Enrollment in Key Blood Cancer Therapy Trial Read More »

US Markets

Bristol-Myers Squibb (NYSE: BMY) Stock Soars on Q2 Earnings Beat, Raised Guidance

Salman Akhtar / 29 July 2024

Bristol-Myers Squibb (NYSE: BMY) stock jumped during intraday trading after the pharmaceutical giant announced strong second-quarter results and raised its

Bristol-Myers Squibb (NYSE: BMY) Stock Soars on Q2 Earnings Beat, Raised Guidance Read More »

2seventy Bio (NASDAQ: TSVT) Discontinues Enrollment in Key Blood Cancer Therapy Trial

Bristol-Myers Squibb (NYSE: BMY) Stock Soars on Q2 Earnings Beat, Raised Guidance

Company

About Us

Team

Contact Us

Categories

US Market

Business

Technology

News

Featured

Press Release

Legal

Privacy Policy

Disclaimer